Concentra Group Holdings Parent, Inc., a specialty outpatient services provider with a market capitalization of $2.6 billion, has announced adjustments to its executive compensation structure. According to InvestingPro data, the company maintains a GREAT financial health score and has been profitable over the last twelve months. On January 9, 2025, the company’s Human Capital and Compensation Committee approved new base salaries for several top executives as part of its 2025 financial planning.
The revised salaries, effective from the same date, are as follows: William K. Newton, Chief Executive Officer, will receive $850,000; Matthew T. DiCanio, President and Chief Financial Officer, will have a base salary of $575,000; John A. deLorimier, Executive Vice President, Chief Information and Technology Officer, is set at $450,000; Su Zan Nelson, Executive Vice President and Chief Accounting Officer, and Giovanni Gallara, Executive Vice President and Chief Clinical Services Officer, will both receive $400,000.
These executives are also eligible to participate in the company’s incentive plans, including the Executive Leadership Team Incentive Plan and the Executive Leadership Team Long Term Cash Incentive Plan, which are designed to align the interests of the leadership with those of the shareholders and the overall performance of the company. With revenue of $1.88 billion in the last twelve months and a P/E ratio of 12.32, the company demonstrates solid financial metrics.
The adjustments in the executive pay come as part of the company’s regular review of its compensation policies to ensure they remain competitive and aligned with the market. The move is standard practice for publicly traded companies like Concentra Group Holdings Parent, Inc., which is listed on the New York Stock Exchange under the ticker symbol CON.
InvestingPro analysts maintain a bullish outlook on the stock, with the next earnings report expected on February 26, 2025. Concentra Group Holdings Parent, Inc. operates under the SIC code 8093 for specialty outpatient facilities, not elsewhere classified, and is incorporated in Delaware with fiscal year-end on December 31. For deeper insights into Concentra’s financial health and detailed analysis, investors can access the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Concentra Group Holdings Parent Inc has seen significant developments. The company’s stock was upgraded from Neutral to Buy by BofA Securities, following the completion of its spin-off from Select Medical (NYSE:SEM). This move allows Concentra to operate more independently, potentially improving its market performance. BofA Securities also set a price target of $24.00 for Concentra, reflecting an improved economic outlook post-elections and the company’s resilience to potential challenges in the healthcare sector.
On the other hand, Concentra has made strategic changes to its executive compensation and incentives, awarding restricted shares to several top executives under its 2024 Equity Incentive Plan. The largest allocation went to W. Keith Newton, followed by Matthew T. DiCanio. This move aims to align the interests of its executive team with those of the shareholders, incentivizing long-term performance and retention.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.